Compelling evidence presented at #isth2025 by Sebastian Leyes Porello from @samelsonjones.bsky.social’s group showing mim8 can enhance activity in hemophilia B variants in vitro, above enhancement this group saw with emicizumab. Curious about in vivo data teased during the Q&A 👀
#hemesky @isth.org
#hemesky @isth.org
June 21, 2025 at 5:28 PM
Compelling evidence presented at #isth2025 by Sebastian Leyes Porello from @samelsonjones.bsky.social’s group showing mim8 can enhance activity in hemophilia B variants in vitro, above enhancement this group saw with emicizumab. Curious about in vivo data teased during the Q&A 👀
#hemesky @isth.org
#hemesky @isth.org
Phase 3 trial: Mim8, a bispecific antibody for hemophilia A (± inhibitors). Patients ≥12 received weekly/monthly doses based on weight. PMID:42054679, N Engl J Med 2026, @NEJM https://doi.org/10.1056/NEJMoa2517384 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2517384
No description available
doi.org
May 27, 2026 at 12:10 AM
Potential emerging signal difference in ADAs in next-generation FVIII(a)-mimetics. 0/61 for Mim8 but 2/30 for NXT007. Surveillance may not be the same.
#ISTH2025 #hemophilia #hemesky
#ISTH2025 #hemophilia #hemesky
June 22, 2025 at 8:42 PM
Potential emerging signal difference in ADAs in next-generation FVIII(a)-mimetics. 0/61 for Mim8 but 2/30 for NXT007. Surveillance may not be the same.
#ISTH2025 #hemophilia #hemesky
#ISTH2025 #hemophilia #hemesky
Research evaluating Mim8, a factor VIIIa–mimetic bispecific antibody, as prophylaxis in hemophilia A with or without inhibitors is summarized in a new Quick Take video. https://nej.md/48kosVT
#Hematology
#Hematology
May 3, 2026 at 1:11 PM
Research evaluating Mim8, a factor VIIIa–mimetic bispecific antibody, as prophylaxis in hemophilia A with or without inhibitors is summarized in a new Quick Take video. https://nej.md/48kosVT
#Hematology
#Hematology
Among patients with hemophilia A, the annualized rate of treated bleeding events with Mim8 was more than 96% lower than with on-demand therapy and more than 42% lower than with clotting factor prophylaxis. Full FRONTIER2 trial: https://nej.md/4tvzfF4
Science behind the Study: https://nej.md/3OKQkfg
Science behind the Study: https://nej.md/3OKQkfg
April 29, 2026 at 9:10 PM
Among patients with hemophilia A, the annualized rate of treated bleeding events with Mim8 was more than 96% lower than with on-demand therapy and more than 42% lower than with clotting factor prophylaxis. Full FRONTIER2 trial: https://nej.md/4tvzfF4
Science behind the Study: https://nej.md/3OKQkfg
Science behind the Study: https://nej.md/3OKQkfg
In a new editorial, Alok Srivastava, MD, describes the scientific foundations and implications of the results of a randomized, controlled trial of Mim8, a new mimetic of factor VIIIa, to treat hemophilia A.
Learn about the science behind the study: https://nej.md/3OKQkfg
#Hematology
Learn about the science behind the study: https://nej.md/3OKQkfg
#Hematology
April 29, 2026 at 11:13 PM
In a new editorial, Alok Srivastava, MD, describes the scientific foundations and implications of the results of a randomized, controlled trial of Mim8, a new mimetic of factor VIIIa, to treat hemophilia A.
Learn about the science behind the study: https://nej.md/3OKQkfg
#Hematology
Learn about the science behind the study: https://nej.md/3OKQkfg
#Hematology
📄 Check out the graphical summary of the recently published NEJM Group article on Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. A clear visual overview of the latest clinical data and key findings shaping the evolving haemophilia treatment landscape.
May 6, 2026 at 2:59 PM
📄 Check out the graphical summary of the recently published NEJM Group article on Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. A clear visual overview of the latest clinical data and key findings shaping the evolving haemophilia treatment landscape.
11 – #MajorPROsASH – 540 Hermans
Mim8 (F8 BsAb mimetic) ppx #hemophilia A: clinically-meaningful improvements in PRO-assessed treatment burden, physical fxn & joint pain at 1 year. PROs similar between qweek & qmonth dosing. >88% preferred Mim8 over previous on-demand tx. #ASH25 @ash.hematology.org
Mim8 (F8 BsAb mimetic) ppx #hemophilia A: clinically-meaningful improvements in PRO-assessed treatment burden, physical fxn & joint pain at 1 year. PROs similar between qweek & qmonth dosing. >88% preferred Mim8 over previous on-demand tx. #ASH25 @ash.hematology.org
December 3, 2025 at 7:53 PM
11 – #MajorPROsASH – 540 Hermans
Mim8 (F8 BsAb mimetic) ppx #hemophilia A: clinically-meaningful improvements in PRO-assessed treatment burden, physical fxn & joint pain at 1 year. PROs similar between qweek & qmonth dosing. >88% preferred Mim8 over previous on-demand tx. #ASH25 @ash.hematology.org
Mim8 (F8 BsAb mimetic) ppx #hemophilia A: clinically-meaningful improvements in PRO-assessed treatment burden, physical fxn & joint pain at 1 year. PROs similar between qweek & qmonth dosing. >88% preferred Mim8 over previous on-demand tx. #ASH25 @ash.hematology.org
First-Line Zongertinib in Advanced HER2-Mutant NSCLC https://nej.md/4cn0Ssz
An Intervention to Improve Maternal Infection Outcomes https://nej.md/4o6xhaF
Mim8 in Hemophilia A with or without Inhibitors https://nej.md/4tvzfF4
Pulmonary TB Detection with MiniDock MTB https://nej.md/48RWCjW
An Intervention to Improve Maternal Infection Outcomes https://nej.md/4o6xhaF
Mim8 in Hemophilia A with or without Inhibitors https://nej.md/4tvzfF4
Pulmonary TB Detection with MiniDock MTB https://nej.md/48RWCjW
April 30, 2026 at 1:01 PM
First-Line Zongertinib in Advanced HER2-Mutant NSCLC https://nej.md/4cn0Ssz
An Intervention to Improve Maternal Infection Outcomes https://nej.md/4o6xhaF
Mim8 in Hemophilia A with or without Inhibitors https://nej.md/4tvzfF4
Pulmonary TB Detection with MiniDock MTB https://nej.md/48RWCjW
An Intervention to Improve Maternal Infection Outcomes https://nej.md/4o6xhaF
Mim8 in Hemophilia A with or without Inhibitors https://nej.md/4tvzfF4
Pulmonary TB Detection with MiniDock MTB https://nej.md/48RWCjW
Late Breaking Session Highlight 💡 Join Johnny Mahlangu presenting Mim8 prophylaxis in children with haemophilia A: 52-week efficacy and safety results from the FRONTIER3: eahadcongress.com/scientific-p...
January 21, 2026 at 10:00 AM
Late Breaking Session Highlight 💡 Join Johnny Mahlangu presenting Mim8 prophylaxis in children with haemophilia A: 52-week efficacy and safety results from the FRONTIER3: eahadcongress.com/scientific-p...
Today's Saint Patrick's Day Season 2026 Morning Music Selection is Tom Waits - Clap Hands music video www.youtube.com/watch?v=Mim8... Video by emma_h91 www.youtube.com/@shadowcolle...
Tom Waits - Clap Hands music video
YouTube video by emma_h91
www.youtube.com
March 14, 2026 at 11:26 AM
Today's Saint Patrick's Day Season 2026 Morning Music Selection is Tom Waits - Clap Hands music video www.youtube.com/watch?v=Mim8... Video by emma_h91 www.youtube.com/@shadowcolle...
Ruoyan Liu showed off Synvida’s tri-specific single-chain nanobody, while Jacob Lund from Novo Nordisk presented a bispecific-plus-albumin-binding FVIII mimetic for oral hemophilia prophylaxis.
#isth2025
#isth2025
June 23, 2025 at 9:35 PM
Ruoyan Liu showed off Synvida’s tri-specific single-chain nanobody, while Jacob Lund from Novo Nordisk presented a bispecific-plus-albumin-binding FVIII mimetic for oral hemophilia prophylaxis.
#isth2025
#isth2025
Thoughts on this? >> Novo Nordisk takes aim at Roche in hemophilia A, but is way
behind: Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its… >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #productmarketing #healthcare
behind: Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its… >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #productmarketing #healthcare
Novo Nordisk takes aim at Roche in hemophilia A, but is way
behind
Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its pediatric trial, opening the way to a larger patient population after the treatment succeeded in its pivotal ...
dlvr.it
February 7, 2025 at 1:37 PM
Thoughts on this? >> Novo Nordisk takes aim at Roche in hemophilia A, but is way
behind: Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its… >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #productmarketing #healthcare
behind: Novo Nordisk said Friday that its hemophilia A preventive Mim8 was effective in its… >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #pharma #productmarketing #healthcare
Start off today with
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B
June 21, 2025 at 11:57 AM
Start off today with
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B
OC 03.1 - Mim8 Enhances Procoagulant Activity of Select #Hemophilia B-causing Factor IX Variants
And finish on Wednesday with
OC 69.5 - Six-year outcomes following fidanacogene elaparvovec in adults with #hemophilia B
Novo Nordisk Showcases Phase 3 Hemophilia Trial Results at ISTH 2025 Congress#United_States#Novo_Nordisk#Hemophilia#Plainsboro#Mim8
Novo Nordisk Showcases Phase 3 Hemophilia Trial Results at ISTH 2025 Congress
Latest findings from Novo Nordisk's phase 3 trials on Hemophilia treatments will be presented at ISTH 2025, showcasing advancements in rare blood disorders.
third-news.com
June 6, 2025 at 1:20 PM
Novo Nordisk Showcases Phase 3 Hemophilia Trial Results at ISTH 2025 Congress#United_States#Novo_Nordisk#Hemophilia#Plainsboro#Mim8
Mim8 (denecimig) was effective in preventing bleeding in patients with #hemophilia A, producing mean ABRs of 0.57 and 0.20 in patients receiving weekly and monthly Mim8 injections, respectively, compared with 15.76 in those receiving on-demand treatment: https://ow.ly/i3Uw50ZIrP8
#HemeSky
#HemeSky
September 4, 2026 at 3:00 PM
Mim8 (denecimig) was effective in preventing bleeding in patients with #hemophilia A, producing mean ABRs of 0.57 and 0.20 in patients receiving weekly and monthly Mim8 injections, respectively, compared with 15.76 in those receiving on-demand treatment: https://ow.ly/i3Uw50ZIrP8
#HemeSky
#HemeSky